Literature DB >> 22899371

Inhibition of topoisomerase II α activity and induction of apoptosis in mammalian cells by semi-synthetic andrographolide analogues.

Jintapat Nateewattana1, Rungnapha Saeeng, Sakkasem Kasemsook, Kanoknetr Suksen, Suman Dutta, Surawat Jariyawat, Arthit Chairoungdua, Apichart Suksamrarn, Pawinee Piyachaturawat.   

Abstract

Topoisomerase II α enzyme plays a critical role in DNA replication process. It controls the topologic states of DNA during transcription and is essential for cell proliferation. Human DNA topoisomerase II α (hTopo II α) is a promising chemotherapeutic target for anticancer agents against a variety of cancer types. In the present study, andrographolide and its structurally modified analogues were investigated for their inhibitory activities on hTopo II α enzyme. Five out of nine andrographolide analogues potently reduced hTopo II α activity and inhibited cell proliferation in four mammalian cell lines (Hela, CHO, BCA-1 and HepG2 cells). IC50 values for cytotoxicity of analogues 3A.1, 3A.2, 3A.3, 1B and 2C were 4 to 7 μM. Structure-activity relationship studies revealed that both core structure of andrographolide and silicon based molecule of functional group were important for the inhibition of hTopo II α activity whereas position C-19 of analogues was required for anti-proliferation. In addition, the analogue 2C at 10 μM concentration inhibited hTopo II α, and induced apoptosis with nuclear fragmentation and formation of apoptotic bodies in HepG2 cells. The analogue 2C may, therefore, have a therapeutic potential as effective anticancer agent targeting the hTopo II α functions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22899371     DOI: 10.1007/s10637-012-9868-9

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  22 in total

1.  Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II.

Authors:  Xia Xue; Xian-Jun Qu; Zu-Hua Gao; Cui-Cui Sun; Hui-Ping Liu; Cui-Rong Zhao; Yan-Na Cheng; Hong-Xiang Lou
Journal:  Invest New Drugs       Date:  2010-10-06       Impact factor: 3.850

2.  Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.

Authors:  B B Hasinoff; T I Kuschak; A M Creighton; C L Fattman; W P Allan; P Thampatty; J C Yalowich
Journal:  Biochem Pharmacol       Date:  1997-06-15       Impact factor: 5.858

3.  NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.

Authors:  Takeshi Onda; Eriko Toyoda; Osamu Miyazaki; Chieko Seno; Shigehide Kagaya; Kazuya Okamoto; Kiyohiro Nishikawa
Journal:  Cancer Lett       Date:  2007-11-12       Impact factor: 8.679

4.  Benzylidene derivatives of andrographolide inhibit growth of breast and colon cancer cells in vitro by inducing G(1) arrest and apoptosis.

Authors:  S R Jada; C Matthews; M S Saad; A S Hamzah; N H Lajis; M F G Stevens; J Stanslas
Journal:  Br J Pharmacol       Date:  2008-09-22       Impact factor: 8.739

Review 5.  Clinical applications of anticancer drugs targeted to topoisomerase II.

Authors:  K R Hande
Journal:  Biochim Biophys Acta       Date:  1998-10-01

6.  Inhibition of cellular proliferation by diterpenes, topoisomerase II inhibitor.

Authors:  Shohei Miyata; Li-Yan Wang; Chisato Yoshida; Susumu Kitanaka
Journal:  Bioorg Med Chem       Date:  2005-11-28       Impact factor: 3.641

Review 7.  Modifications of andrographolide to increase some biological activities: a patent review (2006 - 2011).

Authors:  Chantana Aromdee
Journal:  Expert Opin Ther Pat       Date:  2012-02-14       Impact factor: 6.674

8.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

9.  Synthesis and structure-activity relationships of andrographolide analogues as novel cytotoxic agents.

Authors:  Srinivas Nanduri; Vijay Kumar Nyavanandi; Siva Sanjeeva Rao Thunuguntla; Sridevi Kasu; Mahesh Kumar Pallerla; P Sai Ram; Sriram Rajagopal; R Ajaya Kumar; Rajagopalan Ramanujam; J Moses Babu; Krishnamurthi Vyas; A Sivalakshmi Devi; G Om Reddy; Venkateswarlu Akella
Journal:  Bioorg Med Chem Lett       Date:  2004-09-20       Impact factor: 2.823

10.  Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints.

Authors:  Michal Sabisz; Józefa Wesierska-Gadek; Andrzej Skladanowski
Journal:  Biochem Pharmacol       Date:  2010-01-11       Impact factor: 5.858

View more
  3 in total

1.  The anti-cancer activity of an andrographolide analogue functions through a GSK-3β-independent Wnt/β-catenin signaling pathway in colorectal cancer cells.

Authors:  Somrudee Reabroi; Rungnapha Saeeng; Nittaya Boonmuen; Teerapich Kasemsuk; Witchuda Saengsawang; Kanoknetr Suksen; Weiming Zhu; Pawinee Piyachaturawat; Arthit Chairoungdua
Journal:  Sci Rep       Date:  2018-05-21       Impact factor: 4.379

2.  Inhibition of Topoisomerase IIα and Induction of Apoptosis in Gastric Cancer Cells by 19-Triisopropyl Andrographolide

Authors:  Adeep Monger; Nittaya Boonmuen; Kanoknetr Suksen; Rungnapha Saeeng; Teerapich Kasemsuk; Pawinee Piyachaturawat; Witchuda Saengsawang; Arthit Chairoungdua
Journal:  Asian Pac J Cancer Prev       Date:  2017-10-26

3.  Precursor-Directed Generation of Indolocarbazoles with Topoisomerase IIα Inhibitory Activity.

Authors:  Cong Wang; Adeep Monger; Liping Wang; Peng Fu; Pawinee Piyachaturawat; Arthit Chairoungdua; Weiming Zhu
Journal:  Mar Drugs       Date:  2018-05-17       Impact factor: 5.118

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.